Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial momentum for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company is preparing a regulatory ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, possibly helping cut the... CRISPR gene-editing works to reduce high cholesterol ...